Navigation Links
Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Date:11/2/2009

TOKYO, November 2 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries, the product being both safe and effective as an oral emergency contraceptive for post-coital use.

Sosei have acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA application for SOH-075 was submitted in Japan in September 2009.

The agreement is based on the terms of a binding letter of agreement that was announced on 22 October 2008. According to this agreement, Sosei is responsible for development and registration and ASKA for sales and marketing.

In accordance with the agreement, Sosei will receive upfront, milestone payments as well as a margin on product sales to ASKA.

Notes for Editors:

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan. For further information about Sosei, please visit http://www.sosei.com.

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
5. Sosei Assigns AD 923 Assets to Pharmasol
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... January 19, 2017 While ... serious about reducing the FDA,s regulatory strictness as ... the medical drug industry, many of the leading ... clinical trials and development of advanced drug treatments ... with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/19/2017)... Huntington Beach, CA (PRWEB) , ... January 19, ... ... for Oral Health, is now offering treatments for patients with sleep apnea and ... far-reaching consequences for dental and physical health. Dr. Rassouli provides personalized care to ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... protection and financial planning services to communities throughout eastern Georgia, is embarking on ... heart disease. , Heart disease kills more Americans every year than anything else, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages to prevent ... contest from Impact Teen Drivers and California Casualty. Entries from students aged 14-22 ... grants totaling $15,000 will be awarded for the best peer-to-peer messages sharing solutions ...
(Date:1/19/2017)... ... 19, 2017 , ... The 21st Century Cures Act’s Impact on Medical Devices:, ... 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , ... to thrive this year? , The passage of the act means devicemakers will be ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... American Osteopathic College of Proctology) announced today the opening of 3 medical ... ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center ...
Breaking Medicine News(10 mins):